NextCell Pharma AB ("NextCell" or the "Company") invites investors, analysts and media to an investor presentation in conjunction with the publication of the Company's second interim report for the 2024/2025 financial year, on Thursday, 25 April 2025.
CEO Mathias Svahn will present the Company, the report, and the results from the subgroup analysis published on 7 April 2025. The Company’s subsidiaries, Cellaviva and QVance, will also be presented by their respective CEOs: Sofie Falk Jansson (Cellaviva) and Lindsay Davies (QVance). Attendees, both on-site and online, will have the opportunity to ask questions. The presentation will be available for on-demand streaming.
Time: Friday, 25 April 2025, at 2:00 PM
Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden
Registration (for on-site attendance): Please register by email to events@redeye.se
Webcast (no pre-registration required): Please follow this link:
https://www.redeye.se/events/1095576/business-update-nextcell-pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 0+46 8-735 5595
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For information about Cellaviva, please contact:
Sofie Falk Jansson, CEO
Tel: 08-735 2010
E-mail: info@cellaviva.se
Website: www.cellaviva.se
Facebook: https://www.facebook.com/cellavivasverige
Twitter: https://www.instagram.com/cellaviva/
Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.